OIS-Generic-Author-Image-MALE

Keith Croes

Contributing Writer

  • All
  • Deals
  • Devices and Diagnostics
  • Digital
  • Genetics
  • Pharma
CRISPR and inherited retinal disease

March 18 2020

CRISPR and inherited retinal disease

Once again the eye proved to be the pioneer target in a new gene therapy approach, with the use in February of an agent utilizing ...
Read More
AbbVie and Allergan Are Going to Be Just Fine

January 30 2020

AbbVie and Allergan Are Going to Be Just Fine

Media coverage of AbbVie’s (NYSE: ABBV) acquisition of Allergan (NYSE: AGN) in June was both bullish and bearish. In our initial coverage, we took a ...
Read More
Soft CL slows myopia in children

January 22 2020

Soft CL slows myopia in children

Globally, the myopia market may be worth upwards of $28 billion by 2026, with single prescription corrective lenses holding a significant market share, according to ...
Read More
Lucentis and Eylea patent expirations in the micro-crystal ball

January 14 2020

Lucentis and Eylea patent expirations in the micro-crystal ball

Over the past 10 years, the Dow Jones Industrial Average has seen a 10-year climb with small calendar-year dips seen in 2015 (-2.23%) and 2018 ...
Read More
RegenxBio sues FDA over clinical hold

November 27 2019

RegenxBio sues FDA over clinical hold

Days after the U.S. Food and Drug Administration placed a partial hold on RGX-314, RegenxBio (NASDAQ: RGNX) lead gene therapy agent, the company initially outlined ...
Read More
Opthea’s Star Brightens for Stakeholders

October 30 2019

Opthea’s Star Brightens for Stakeholders

It’s been a good year for Opthea Ltd., a biotechnology company based in Melbourne, Australia. It’s listed on the Australian Securities Exchange (ASX), trading as ...
Read More
Eyeing Gene Therapy’s Ocular Future

October 9 2019

Eyeing Gene Therapy’s Ocular Future

CHICAGO—The first gene therapy approved in the United States happened to be for an inherited eye disease, with an agent that is administered subretinally. But ...
Read More
Retina Treatment Beyond Protocol

October 2 2019

Retina Treatment Beyond Protocol

CHICAGO — Optimal treatment of retinal diseases hinges on better understanding in three primary areas, said an expert panel at OIS@ASRS 2019: the disease mechanisms ...
Read More
Glaukos' Bid for Avedro: What's Next

August 14 2019

A Closer Look at Glaukos’ Bid for Avedro

Early market reaction to Glaukos Corp.'s all-stock acquisition of Avedro Inc. was mixed; a decrease in stock price for Glaukos and an increase for Avedro. ...
Read More
OIS@ASRS at the Ritz-Carlton Chicago: An In-depth Look at the Retina Space

July 17 2019

OIS@ASRS at the Ritz-Carlton Chicago: An In-depth Look at the Retina Space

CHICAGO – The extensive, intensive public and private investment in the retinal space will fill the day next Thursday, July 25, at the OIS@ASRS meeting, ...
Read More
A Closer Look at AbbVie-Allergan Deal and Where Eye Care Fits In

June 26 2019

A Closer Look at AbbVie-Allergan Deal and Where Eye Care Fits In

NEW YORK – In what’s been called “a transformative move for both companies,” AbbVie has agreed to buy Allergan in a deal valued at $63 ...
Read More
Why Ophthalmology Bulls Keep Running

June 13 2019

Why Equity and M&A Markets in Ophthalmology Are Poised for a Great Run

SAN DIEGO – Although the 10-year bull market is bound to end one of these days, the trend in ophthalmology and healthcare in general is ...
Read More